Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Enanta Pharmaceuticals' Accumulated Expenses history spans 14 years, with the latest figure at $32.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.33% year-over-year to $32.0 million; the TTM value through Dec 2025 reached $32.0 million, down 2.33%, while the annual FY2025 figure was $30.7 million, 367.43% up from the prior year.
  • Accumulated Expenses reached $32.0 million in Q4 2025 per ENTA's latest filing, up from $30.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $36.5 million in Q4 2023 to a low of $2.4 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $15.8 million, with a median of $13.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 1308.1% in 2023, then plummeted 81.27% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $2.4 million in 2021, then grew by 7.02% to $2.6 million in 2022, then skyrocketed by 1308.1% to $36.5 million in 2023, then decreased by 10.32% to $32.7 million in 2024, then fell by 2.33% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Accumulated Expenses are $32.0 million (Q4 2025), $30.7 million (Q3 2025), and $10.9 million (Q2 2025).